Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dermatofibroma Hypocellularity Is Associated With Patient Age: A Retrospective Study of 307 Cases.

Journal of cutaneous pathology·2026

Same author

A Rare Case of Conjunctival Pseudoglandular Hyperplasia Identified During Mohs Micrographic Surgery of an Infraorbital Basal Cell Carcinoma.

Journal of cutaneous pathology·2026

Same author

Sex differences in exogenous glucose oxidation are attenuated by obesity: insights from a [U-<sup>13</sup>C<sub>6</sub>]glucose home breath test.

American journal of physiology. Endocrinology and metabolism·2026

Same author

Eosinophilic, polymorphic, and pruritic eruption associated with radiation treated with dupilumab in a patient with Hodgkin lymphoma.

JAAD case reports·2026

Same author

Physical therapists should earn continuing education credits for non-clinical skills: a window into the profession and a call to action.

The Journal of manual & manipulative therapy·2026

Same author

Multilesional pyoderma gangrenosum secondary to Hodgkin lymphoma.

JAAD case reports·2026

Search research articles

Related Experiment Video

Updated: May 31, 2025

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Published on: April 19, 2017

Recalcitrant Dermatomyositis Treated With Anifrolumab.

Shivang Chaudhary¹, Meghan Baumer¹, Laura Upton¹

¹Saint Louis University School of Medicine, St. Louis, Missouri.

ACR Open Rheumatology

|January 24, 2025

Summary

This summary is machine-generated.

Anifrolumab, a type 1 interferon inhibitor, shows promise for treating severe dermatomyositis (DM) in patients refractory to other treatments. This case study highlights its potential in managing this rare inflammatory myopathy.

More Related Videos

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Related Experiment Videos

Last Updated: May 31, 2025

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Published on: April 19, 2017

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Area of Science:

Immunology
Dermatology
Rheumatology

Background:

Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by distinct skin manifestations.
Despite available treatments, some DM patients exhibit refractory disease, necessitating novel therapeutic approaches.
The type 1 interferon (IFN) pathway is implicated in DM pathogenesis and disease activity.

Observation:

A 38-year-old male patient presented with recalcitrant dermatomyositis, demonstrating resistance to conventional therapies.
The patient's disease activity showed a correlation with type 1 interferon pathway activity.

Findings:

Successful treatment of refractory dermatomyositis was achieved using anifrolumab, a monoclonal antibody targeting the interferon α receptor 1 (IFNAR1).
Anifrolumab effectively managed the patient's severe cutaneous symptoms.

Implications:

Anifrolumab represents a potential therapeutic option for severe cutaneous dermatomyositis, particularly in treatment-refractory cases.
Targeting the type 1 interferon pathway with anifrolumab may offer a new strategy for managing refractory DM.